Evolus, Inc. EOLS
We take great care to ensure that the data presented and summarized in this overview for Evolus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EOLS
View all-
Tang Capital Management LLC San Diego, CA5MShares$45.7 Million3.9% of portfolio
-
Perceptive Advisors LLC New York, NY4.13MShares$37.7 Million2.08% of portfolio
-
Black Rock Inc. New York, NY4.01MShares$36.6 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.65MShares$33.4 Million1.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.23MShares$29.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.39MShares$12.7 Million0.01% of portfolio
-
State Street Corp Boston, MA1.38MShares$12.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.26MShares$11.5 Million0.0% of portfolio
-
Frontier Capital Management CO LLC1.21MShares$11 Million0.17% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.14MShares$10.4 Million0.42% of portfolio
Latest Institutional Activity in EOLS
Top Purchases
Top Sells
About EOLS
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Insider Transactions at EOLS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 16
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
16,582
-4.35%
|
$149,238
$9.89 P/Share
|
Jun 13
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
111,323
-22.59%
|
$1,113,230
$10.05 P/Share
|
Jun 09
2025
|
Albert G White Iii Director |
BUY
Open market or private purchase
|
Direct |
20,000
+28.42%
|
$180,000
$9.45 P/Share
|
May 13
2025
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,494
-3.74%
|
$64,940
$10.02 P/Share
|
May 12
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
15,787
-3.1%
|
$142,083
$9.87 P/Share
|
May 12
2025
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
3,385
-0.93%
|
$30,465
$9.87 P/Share
|
Mar 27
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,251
-1.21%
|
$75,012
$12.4 P/Share
|
Mar 18
2025
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
103,376
-16.72%
|
$1,343,888
$13.26 P/Share
|
Mar 18
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
4,536
-4.53%
|
$58,968
$13.26 P/Share
|
Mar 18
2025
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,996
-4.93%
|
$116,948
$13.26 P/Share
|
Mar 18
2025
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
27,904
-7.15%
|
$362,752
$13.26 P/Share
|
Mar 12
2025
|
Karah Herdman Parschauer Director |
SELL
Open market or private sale
|
Direct |
12,888
-28.59%
|
$154,656
$12.99 P/Share
|
Mar 07
2025
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,663
+16.34%
|
-
|
Mar 07
2025
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,832
+15.11%
|
-
|
Mar 07
2025
|
Karah Herdman Parschauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+14.04%
|
-
|
Mar 07
2025
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+2.82%
|
-
|
Mar 07
2025
|
Albert G White Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+19.51%
|
-
|
Mar 07
2025
|
Brady Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+11.16%
|
-
|
Mar 07
2025
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+15.12%
|
-
|
Mar 07
2025
|
Simone Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,364
+8.72%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 217K shares |
---|---|
Open market or private purchase | 20K shares |
Open market or private sale | 341K shares |
---|